PMC:7228307 / 47519-48030 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"914","span":{"begin":328,"end":336},"obj":"Gene"},{"id":"915","span":{"begin":372,"end":380},"obj":"Gene"},{"id":"916","span":{"begin":418,"end":425},"obj":"Gene"},{"id":"917","span":{"begin":498,"end":503},"obj":"Species"},{"id":"918","span":{"begin":209,"end":237},"obj":"Disease"},{"id":"919","span":{"begin":471,"end":494},"obj":"Disease"},{"id":"920","span":{"begin":283,"end":288},"obj":"Mutation"},{"id":"921","span":{"begin":293,"end":298},"obj":"Mutation"}],"attributes":[{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"Gene:2214"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"Gene:2214"},{"id":"A916","pred":"tao:has_database_id","subj":"916","obj":"Gene:14131"},{"id":"A917","pred":"tao:has_database_id","subj":"917","obj":"Tax:10090"},{"id":"A918","pred":"tao:has_database_id","subj":"918","obj":"MESH:D015451"},{"id":"A919","pred":"tao:has_database_id","subj":"919","obj":"MESH:D006130"},{"id":"A920","pred":"tao:has_standard_notation","subj":"920","obj":"p.S329D"},{"id":"A921","pred":"tao:has_standard_notation","subj":"921","obj":"p.I332E"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T386","span":{"begin":18,"end":29},"obj":"Body_part"},{"id":"T387","span":{"begin":62,"end":65},"obj":"Body_part"},{"id":"T388","span":{"begin":127,"end":135},"obj":"Body_part"},{"id":"T389","span":{"begin":217,"end":228},"obj":"Body_part"}],"attributes":[{"id":"A386","pred":"fma_id","subj":"T386","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A387","pred":"fma_id","subj":"T387","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A388","pred":"fma_id","subj":"T388","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A389","pred":"fma_id","subj":"T389","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T84","span":{"begin":209,"end":237},"obj":"Disease"},{"id":"T85","span":{"begin":217,"end":237},"obj":"Disease"},{"id":"T86","span":{"begin":229,"end":237},"obj":"Disease"},{"id":"T87","span":{"begin":435,"end":439},"obj":"Disease"},{"id":"T88","span":{"begin":479,"end":487},"obj":"Disease"}],"attributes":[{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005402"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005059"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0008734"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005062"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T817","span":{"begin":49,"end":51},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T818","span":{"begin":95,"end":105},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T819","span":{"begin":106,"end":108},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T820","span":{"begin":109,"end":111},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T821","span":{"begin":122,"end":126},"obj":"http://purl.obolibrary.org/obo/CLO_0053432"},{"id":"T822","span":{"begin":279,"end":281},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T823","span":{"begin":328,"end":330},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T824","span":{"begin":372,"end":374},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T825","span":{"begin":418,"end":420},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T826","span":{"begin":498,"end":503},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T243","span":{"begin":18,"end":29},"obj":"Chemical"},{"id":"T244","span":{"begin":18,"end":23},"obj":"Chemical"},{"id":"T245","span":{"begin":24,"end":29},"obj":"Chemical"}],"attributes":[{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_46882"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T223","span":{"begin":488,"end":494},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T52","span":{"begin":18,"end":29},"obj":"Chemical"}],"attributes":[{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_33709"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"914","span":{"begin":328,"end":336},"obj":"Gene"},{"id":"915","span":{"begin":372,"end":380},"obj":"Gene"},{"id":"916","span":{"begin":418,"end":425},"obj":"Gene"},{"id":"917","span":{"begin":498,"end":503},"obj":"Species"},{"id":"918","span":{"begin":209,"end":237},"obj":"Disease"},{"id":"919","span":{"begin":471,"end":494},"obj":"Disease"},{"id":"920","span":{"begin":283,"end":288},"obj":"Mutation"},{"id":"921","span":{"begin":293,"end":298},"obj":"Mutation"}],"attributes":[{"id":"A921","pred":"pubann:has_HGVS_notation","subj":"921","obj":"p.I332E"},{"id":"A917","pred":"pubann:denotes","subj":"917","obj":"Tax:10090"},{"id":"A919","pred":"pubann:denotes","subj":"919","obj":"MESH:D006130"},{"id":"A915","pred":"pubann:denotes","subj":"915","obj":"Gene:2214"},{"id":"A916","pred":"pubann:denotes","subj":"916","obj":"Gene:14131"},{"id":"A914","pred":"pubann:denotes","subj":"914","obj":"Gene:2214"},{"id":"A920","pred":"pubann:has_HGVS_notation","subj":"920","obj":"p.S329D"},{"id":"A918","pred":"pubann:denotes","subj":"918","obj":"MESH:D015451"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T44","span":{"begin":498,"end":503},"obj":"Species"}],"attributes":[{"id":"A44","pred":"ncbi_taxonomy_id","subj":"T44","obj":"NCBItxid:10090"},{"id":"A45","pred":"ncbi_taxonomy_id","subj":"T44","obj":"NCBItxid:10088"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T275","span":{"begin":0,"end":112},"obj":"Sentence"},{"id":"T276","span":{"begin":113,"end":393},"obj":"Sentence"},{"id":"T277","span":{"begin":394,"end":511},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T596","span":{"begin":122,"end":126},"obj":"Protein"}],"attributes":[{"id":"A596","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q9BRD6"},{"id":"A597","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q96S68"},{"id":"A598","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q542B2"},{"id":"A599","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/Q3LRP3"},{"id":"A600","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/P25918"},{"id":"A601","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/P25917"},{"id":"A602","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/P15391"},{"id":"A603","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/F5H635"},{"id":"A604","pred":"uniprot_id","subj":"T596","obj":"https://www.uniprot.org/uniprot/A0N0P9"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T385","span":{"begin":18,"end":29},"obj":"Body_part"},{"id":"T386","span":{"begin":62,"end":65},"obj":"Body_part"},{"id":"T387","span":{"begin":127,"end":135},"obj":"Body_part"},{"id":"T388","span":{"begin":217,"end":228},"obj":"Body_part"}],"attributes":[{"id":"A385","pred":"fma_id","subj":"T385","obj":"http://purl.org/sig/ont/fma/fma82739"},{"id":"A386","pred":"fma_id","subj":"T386","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A387","pred":"fma_id","subj":"T387","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A388","pred":"fma_id","subj":"T388","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T110","span":{"begin":435,"end":439},"obj":"http://purl.obolibrary.org/obo/GO_0001788"},{"id":"T111","span":{"begin":444,"end":456},"obj":"http://purl.obolibrary.org/obo/GO_0006909"},{"id":"T112","span":{"begin":488,"end":494},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T37","span":{"begin":209,"end":237},"obj":"Disease"},{"id":"T38","span":{"begin":479,"end":487},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0004948"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005062"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T33","span":{"begin":209,"end":237},"obj":"Phenotype"},{"id":"T34","span":{"begin":479,"end":487},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0005550"},{"id":"A34","pred":"hp_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/HP_0002665"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T110","span":{"begin":435,"end":439},"obj":"http://purl.obolibrary.org/obo/GO_0001788"},{"id":"T111","span":{"begin":444,"end":456},"obj":"http://purl.obolibrary.org/obo/GO_0006909"},{"id":"T112","span":{"begin":488,"end":494},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T110","span":{"begin":435,"end":439},"obj":"http://purl.obolibrary.org/obo/GO_0001788"},{"id":"T111","span":{"begin":444,"end":456},"obj":"http://purl.obolibrary.org/obo/GO_0006909"},{"id":"T112","span":{"begin":488,"end":494},"obj":"http://purl.obolibrary.org/obo/GO_0040007"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-sentences","denotations":[{"id":"T275","span":{"begin":0,"end":112},"obj":"Sentence"},{"id":"T276","span":{"begin":113,"end":393},"obj":"Sentence"},{"id":"T277","span":{"begin":394,"end":511},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T33","span":{"begin":209,"end":237},"obj":"Phenotype"},{"id":"T34","span":{"begin":479,"end":487},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0005550"},{"id":"A34","pred":"hp_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/HP_0002665"}],"text":"Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs. The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele. The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models."}